| Gut microbiota linked to sexual preference and HIV infection M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ... EBioMedicine 5, 135-146, 2016 | 408 | 2016 |
| Evolution of the gut microbiome following acute HIV-1 infection M Rocafort, M Noguera-Julian, J Rivera, L Pastor, Y Guillén, J Langhorst, ... Microbiome 7, 1-17, 2019 | 89 | 2019 |
| Primary resistance to integrase strand-transfer inhibitors in Europe M Casadellà, PM Van Ham, M Noguera-Julian, A vAn Kessel, C Pou, ... Journal of antimicrobial chemotherapy 70 (10), 2885-2888, 2015 | 82 | 2015 |
| Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial JL Blanco, J Rojas, R Paredes, E Negredo, J Mallolas, M Casadella, ... Journal of Antimicrobial Chemotherapy 73 (7), 1965-1971, 2018 | 76 | 2018 |
| Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection Y Guillén, M Noguera-Julian, J Rivera, M Casadellà, AS Zevin, M Rocafort, ... Mucosal immunology 12 (1), 232-246, 2019 | 74 | 2019 |
| Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study SC Inzaule, RL Hamers, M Noguera-Julian, M Casadellà, M Parera, ... The Lancet HIV 5 (11), e638-e646, 2018 | 71 | 2018 |
| Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa SC Inzaule, RL Hamers, M Noguera-Julian, M Casadellà, M Parera, ... Journal of Antimicrobial Chemotherapy 73 (5), 1167-1172, 2018 | 64 | 2018 |
| Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing ER Lee, N Parkin, C Jennings, CJ Brumme, E Enns, M Casadellà, ... Scientific Reports 10 (1), 1634, 2020 | 57 | 2020 |
| Deep sequencing for HIV-1 clinical management M Casadellà, R Paredes Virus research 239, 69-81, 2017 | 57 | 2017 |
| Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing C Pou, M Noguera-Julian, S Pérez-Álvarez, F García, R Delgado, ... Clinical infectious diseases 59 (4), 578-588, 2014 | 56 | 2014 |
| Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial A Bonjoch, C Pou, N Pérez-Alvarez, R Bellido, M Casadella, J Puig, ... Journal of Antimicrobial Chemotherapy 68 (6), 1382-1387, 2013 | 36 | 2013 |
| Gut microbiota linked to sexual preference and HIV infection. EBioMedicine 5: 135–146 M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ... | 35 | 2016 |
| Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial L Bailón, A Llano, S Cedeño, T Escribà, M Rosás-Umbert, M Parera, ... Nature Medicine 28 (12), 2611-2621, 2022 | 32 | 2022 |
| Gut microbiome signatures linked to HIV-1 reservoir size and viremia control A Borgognone, M Noguera-Julian, B Oriol, L Noël-Romas, M Ruiz-Riol, ... Microbiome 10 (1), 59, 2022 | 26 | 2022 |
| Yaws re-emergence and bacterial drug resistance selection after mass administration of azithromycin: a genomic epidemiology investigation MA Beale, M Noguera-Julian, C Godornes, M Casadellà, ... The Lancet Microbe 1 (6), e263-e271, 2020 | 22 | 2020 |
| Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing M Casadellà, M Noguera-Julian, H Sunpath, M Gordon, C Rodriguez, ... Aids 30 (7), 1137-1140, 2016 | 22 | 2016 |
| No detection of the NS5B S282T mutation in treatment-naive genotype 1 HCV/HIV-1 coinfected patients using deep sequencing S Franco, M Casadellà, M Noguera-Julian, B Clotet, C Tural, R Paredes, ... Journal of clinical virology 58 (4), 726-729, 2013 | 19 | 2013 |
| HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32 E Ballana, E Riveira-Munoz, C Pou, V Bach, M Parera, M Noguera, ... Immunobiology 218 (4), 543-547, 2013 | 17 | 2013 |
| Probiotic effects on immunity and microbiome in HIV-1 discordant patients C Blázquez-Bondia, M Parera, F Català-Moll, M Casadellà, ... Frontiers in Immunology 13, 1066036, 2022 | 14 | 2022 |
| Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant C Beltran-Pavez, CB Ferreira, A Merino-Mansilla, A Fabra-Garcia, ... PLoS One 13 (12), e0208345, 2018 | 12 | 2018 |
